47 results about "Palonosetron" patented technology

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The present invention provides a pharmaceutical composition for delivering palonosetron through the buccal mucosa or sublingual mucosa. The pharmaceutical composition comprises 0.05-35% (w / w) of palonosetron, 40-90% of a film forming agent, 1-10% (w / w) of a plasticizer, 5-25% (w / v) of an adhesive agent, and 0.1-5% of a penetration enhancing agent. A preferred plasticizer is a polysorbate. A preferred adhesive agent is polyvinylpyrrolidone or carboxymethylcellulose. A preferred penetration enhancing agent is peppermint oil or menthol.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Methods are provided to treat post-operative nausea and vomiting, as well as emesis generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron.

The invention belongs to the technical field of medicine, and relates to a palonosetron percutaneous absorption patch and a preparation method thereof. The patch of the invention is composed of a backing layer, a drug-loaded pressure-sensitive adhesive layer and an anti-adhesive layer; Absorption enhancer. Wherein the β-cyclodextrin inclusion complex of palonosetron free base accounts for 4.78%-20.09% of the total weight, preferably 9%-19%, the pressure-sensitive adhesive accounts for 68.80%-95.22% by weight, and the transdermal absorption accelerator Accounting for 0~11.11wt% of the total weight. In the β-cyclodextrin inclusion compound of palonosetron free base, the ratio of the palonosetron free base to the β-cyclodextrin inclusion compound is 1:1-3. The palonosetron percutaneous absorption patch provided by the present invention is selected from the β-cyclodextrin inclusion complex of palonosetron free base, which successfully achieves a drug-free absorption within 7 days compared with the drug-unincluded patch. Release slowly.

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

The invention relates to a solid medicine composition comprising palonosetron. The solid medicine composition comprising the palonosetron comprises the palonosetron or pharmaceutical salt and a pharmaceutically acceptable excipient thereof, and does not contain an adhesive.

Provided are a pharmaceutical composition with improved stability including palonosetron, a preparation method thereof, and a pharmaceutical package including the pharmaceutical composition.

A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-HT3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid drug delivery vehicle that provides a sustained release of granisetron.